Neonc Technologies (NASDAQ:NTHI) CEO Thomas Chen Buys 5,242 Shares

by · The Markets Daily

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) CEO Thomas Chen purchased 5,242 shares of the business’s stock in a transaction dated Monday, September 14th. The stock was bought at an average cost of $3.81 per share, with a total value of $19,972.02. Following the completion of the acquisition, the chief executive officer owned 24,503 shares of the company’s stock, valued at approximately $93,356.43. The trade was a 27.22% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Neonc Technologies Stock Down 12.4%

Shares of NTHI traded down $0.47 during trading hours on Tuesday, reaching $3.31. 285,988 shares of the company traded hands, compared to its average volume of 104,731. The stock has a fifty day simple moving average of $4.04 and a 200 day simple moving average of $5.27. Neonc Technologies Holdings, Inc. has a fifty-two week low of $3.01 and a fifty-two week high of $12.99.

Neonc Technologies (NASDAQ:NTHI – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Institutional Trading of Neonc Technologies

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE purchased a new position in Neonc Technologies in the second quarter valued at approximately $1,017,000. BlackRock Inc. purchased a new stake in Neonc Technologies during the second quarter worth approximately $815,000. Global Retirement Partners LLC purchased a new stake in Neonc Technologies during the second quarter worth approximately $126,000. Finally, Westmount Partners LLC increased its position in shares of Neonc Technologies by 355.2% in the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after acquiring an additional 153,858 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Wall Street Zen lowered Neonc Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. BTIG Research reaffirmed a “buy” rating and set a $15.00 price target on shares of Neonc Technologies in a research report on Tuesday, September 8th. Alliance Global Partners began coverage on shares of Neonc Technologies in a research note on Tuesday, May 19th. They set a “buy” rating and a $13.00 price target on the stock. Maxim Group began coverage on Neonc Technologies in a report on Monday, May 18th. They set a “buy” rating and a $20.00 price objective for the company. Finally, Weiss Ratings raised Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Neonc Technologies currently has an average rating of “Hold” and an average target price of $16.00.

Read Our Latest Stock Report on NTHI

Neonc Technologies News Summary

Here are the key news stories impacting Neonc Technologies this week:

  • Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
  • Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
  • Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
  • Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
  • Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

About Neonc Technologies

(Get Free Report)

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

Recommended Stories